Connected Thinking

Leading Voices

Latest News

Integrating Venetoclax Into CLL Management Is Expanding Treatment Horizons and Improving Survival

Clinical Relevance: Venetoclax can offer your CLL patients a powerful, targeted treatment that is personalized and more effective care with fewer side effects than many other options. _________________________________________________________________________________________________________ Oncologists treating chronic lymphocytic leukemia (CLL) and select small lymphocytic lymphomas should strongly consider adding Venetoclax (Venclexta) to their arsenal, given its proven capacity to significantly enhance […]

Learn More

Balversa’s FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer

Clinical Relevance: Newly FDA-approved Balversa offers a targeted treatment option for patients with FGFR3-positive metastatic bladder cancer, demonstrating significant efficacy in progression-free and overall survival rates, and should be considered post platinum-containing chemotherapy or anti-PD-(L)1 therapy failures. _________________________________________________________________________________________________ Oncologists now have a new option to consider in their decision-making process thanks to the full US […]

Learn More

Tepmetko Approval for NSCLC Mutation Underscores the Value of Genetic Testing

Clinical Relevance: Tepotinib’s approval marks a pivotal advancement in targeted therapy for NSCLC, offering a highly specific treatment option for patients with MET exon 14 skipping mutations and underscoring the importance of genetic profiling in modern oncology practice. _________________________________________________________________________________________________ The availability of Tepmetko (tepotinib), should prompt ontologists to order genetic testing for all of their […]

Learn More

HER2-Low, A New Classification Of Breast Cancer, Expands The Use Of Enhertu For Metastatic Patients

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Trastuzumab deruxtecan (brand name: Enhertu) is a Food and Drug Administration (FDA) approved drug for certain stage four breast cancer patients whose tumors are classified as HER2- low. Previous therapies targeting cancer tumors with HER2 (Human Epidermal Growth Factor 2)-low proteins, such as trastuzumab (brand name: […]

Learn More

The Evolving Management of Anemia in Myelofibrosis

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Myelofibrosis (MF) belongs to a group of blood cancers called myeloproliferative neoplasms (MPNs). These cancers originate in the myeloid tissue, commonly known as the bone marrow, which lines the inside of large bones, such as the vertebral column or the hip bones. “The [abnormal] cell of […]

Learn More

BTK Inhibitor Jaypirca is Now FDA-Approved & May Help Difficult-to-Treat Mantle Cell Lymphoma

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. Mantle Cell Lymphomas (MCL) are rare blood cancers that affect the white blood cells (WBCs), one of the main cell types within the blood. These cancers are as aggressive as they are rare. Treating them can often prove to be an uphill battle. They often reoccur […]

Learn More

Elacestrant (Orserdu) Is Effective For A Stubborn Form of Metastatic Breast Cancer

Contributed by Dr. Muneeb Niazi, Medical Fellow at SurvivorNet. For some women with a particular type of advanced, or metastatic, breast cancer, a new treatment option is showing really promising results. Metastatic breast cancer can be hard to treat, especially when some of the traditional hormone/endocrine therapies do not work. This may happen with particular […]

Learn More

Ibrutinib For Mantle Cell Lymphoma

Mantle cell lymphoma (MCL) is a rare but deadly form of non-Hodgkin lymphoma, a blood cancer affecting the white blood cells (WBCs). It tends to be aggressive and is usually diagnosed later in the disease course, when it is often resistant to treatment. Traditional treatment with the best chance for long-term disease control for MCL […]

Learn More